A multi-institutional group led by the University of California at San Francisco’s Quantitative Biosciences Institute (QBI) has identified more than 200 host proteins that interacted with SARS-CoV-2 viral proteins during infection, creating “a blueprint of how SARS-CoV-2 hijacks human cells.”
The climate crisis in the time of COVID-19 illustrates the difference between the important and the urgent. There is, of course, no alternative to focusing on the current pandemic. But at the same time, the SARS-CoV-2 coronavirus has not changed the fact that the climate crisis is a coming wave whose health consequences will ultimately dwarf those of any single infectious agent.
Keeping you up to date on recent developments in oncology, including: Infectious disease diagnoses often foreshadow cancer diagnoses; Polymerase k and drug resistance; Microcytosis link to cancer confirmed; Researchers describe new triple threat to cancer.
Keeping you up to date on recent developments in cardiology, including: Older siblings’ example turns stem cells into heart cells; Study: High blood pressure meds safe for patients, even during COVID-19 pandemic; COVID-19 spurs fast-tracking of heart, brain health research.
The climate crisis in the time of COVID-19 illustrates the difference between the important and the urgent. There is, of course, no alternative to focusing on the current pandemic. But at the same time, the SARS-CoV-2 coronavirus has not changed the fact that the climate crisis is a coming wave whose health consequences will ultimately dwarf those of any single infectious agent.
BioWorld looks at translational medicine, including: Neutralizing RSV; Insulin cuts both ways in vasculature; Transcriptomic insights into Parkinson’s disease; Restoring synaptic transmission for rare neurodevelopmental disease; Polymerase k and drug resistance; Sphingolipids accumulate in neurodegeneration; How does innate immunity remember? Not via polycomb; Antibiotics affect oxycodone effects; Cabo as next annual shot?
The activity of many proteins is controlled through phosphorylation by kinases and dephosphorylation by phosphatases. Overactive kinases are one of the major drivers of tumors and, as a result, kinase inhibitors are a mainstay of oncology drug development. But “activation of the brakes, the phosphatases, could be equally therapeutically viable for the treatment of a broad range of cancers” to kinase inhibition, Goutham Narla told the audience at the 2020 American Association for Cancer Research (AACR) meeting.
Keeping you up to date on recent developments in diagnostics, including: Deep neural network for colorectal polyp classification; Biomarkers signal chemo-induced heart damage; AI helps gauge risk of severe COVID-19 infection; Platelets play role in Tylenol toxicity.
A multi-institutional group led by the University of California at San Francisco’s Quantitative Biosciences Institute (QBI) has identified more than 200 host proteins that interacted with SARS-CoV-2 viral proteins during infection, creating “a blueprint of how SARS-CoV-2 hijacks human cells,” QBI Director Nevan Krogan told reporters. They then used that blueprint to identify 10 drugs, some FDA approved and some in clinical trials, that were able to inhibit viral growth in cell culture assays, marking them for further study as potential antivirals. The work also identified one compound, dextromethorphan, that appeared to facilitate viral growth.
